Drug intelligence / Profile preview

CVN417

Development stage: Discontinued
Lead developer: Cerevance
Modality: Small Molecules
Administration: Oral

Overview

CVN417 is an orally active, brain-penetrant small molecule antagonist that selectively targets α6-containing nicotinic acetylcholine receptors (nAChRs). Developed by Cerevance using their proprietary NETSseq platform, the compound was designed to modulate phasic dopaminergic neurotransmission in an impulse-dependent manner. Preclinical studies demonstrated its efficacy in attenuating resting tremors in rodent models of Parkinson's disease. CVN417 shows high selectivity for the α6 subunit (IC50 = 0.086 μM) compared to α3 (IC50 = 2.56 μM) and α4 (IC50 = 0.657 μM) subunits. Although it was explored as a potential treatment for motor dysfunction in Parkinson's disease and related movement disorders, its development has been discontinued.

Targets

α6β2 nAChR (α6β2 nicotinic receptor)

Beyond the preview

Go deeper on CVN417.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVN417.

Explore the full profile